Steve Pakola Sells 5,124 Shares of REGENXBIO (NASDAQ:RGNX) Stock

REGENXBIO Inc. (NASDAQ:RGNX) insider Steve Pakola sold 5,124 shares of the stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $10.35, for a total value of $53,033.40. Following the sale, the insider directly owned 247,926 shares of the company’s stock, valued at approximately $2,566,034.10. This represents a 2.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

REGENXBIO Stock Performance

Shares of RGNX opened at $8.57 on Friday. The stock has a market capitalization of $442.30 million, a P/E ratio of -2.28 and a beta of 1.08. The company’s fifty day moving average is $11.00 and its two-hundred day moving average is $11.43. REGENXBIO Inc. has a 1 year low of $5.03 and a 1 year high of $16.19.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings data on Thursday, March 5th. The biotechnology company reported ($1.30) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.29). REGENXBIO had a negative return on equity of 103.12% and a negative net margin of 113.75%.The firm had revenue of $30.34 million for the quarter, compared to analysts’ expectations of $45.48 million. Sell-side analysts predict that REGENXBIO Inc. will post -4.84 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on RGNX. Morgan Stanley lowered their price objective on REGENXBIO from $18.00 to $17.00 and set an “overweight” rating on the stock in a report on Thursday, March 5th. Chardan Capital reduced their price target on REGENXBIO from $52.00 to $50.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Weiss Ratings restated a “sell (d-)” rating on shares of REGENXBIO in a research note on Thursday, January 22nd. Robert W. Baird set a $27.00 price objective on REGENXBIO in a report on Tuesday, February 10th. Finally, Stifel Nicolaus increased their price objective on REGENXBIO from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $27.50.

Institutional Trading of REGENXBIO

A number of hedge funds have recently bought and sold shares of RGNX. State of Alaska Department of Revenue purchased a new stake in REGENXBIO in the 3rd quarter worth approximately $25,000. Aquatic Capital Management LLC purchased a new position in shares of REGENXBIO during the 3rd quarter worth $37,000. Jones Financial Companies Lllp lifted its stake in shares of REGENXBIO by 44.4% during the 3rd quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 1,270 shares during the period. Steward Partners Investment Advisory LLC boosted its holdings in shares of REGENXBIO by 754.1% during the second quarter. Steward Partners Investment Advisory LLC now owns 5,663 shares of the biotechnology company’s stock worth $46,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Captrust Financial Advisors purchased a new stake in shares of REGENXBIO in the second quarter valued at $85,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO News Summary

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Phase 1/2 AFFINITY interim data for RGX‑202 showed early efficacy signals and the company reported no evidence of liver injury in the study — a material safety datapoint that supports the program’s clinical outlook. Positive interim data for Regenxbio’s gene therapy in DMD
• Neutral Sentiment: Insider activity: director/officer Steve Pakola sold 5,124 shares at about $10.35 (disclosed 3/12–3/13). The sale is small (~2% reduction of his holding) but attracts attention in a thinly traded, volatile name. REGENXBIO Insider Sells
• Negative Sentiment: Multiple law firms have filed or are soliciting class‑action claims against REGENXBIO covering a multi‑year period (lead‑plaintiff deadlines around April 14, 2026). The wave of filings raises settlement/legal risk and creates sustained headline pressure. Schall Law Firm class action notice
• Negative Sentiment: Analyst/headline pressure: HC Wainwright published a bearish Q1 earnings forecast, adding sell‑side pressure after REGENXBIO’s recent March 5 quarter where EPS and revenue missed consensus — a reminder of near‑term execution and cash‑flow risks that can weigh on valuation. HC Wainwright bearish forecast

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.